Luxna Biotech has been selected as a finalist in the Startup Category of the 7th IP BASE AWARD organized by the Japan Patent Office.
The IP BASE AWARD recognizes startups and other organizations that demonstrate outstanding initiatives in the strategic use of intellectual property, and this year’s finalists were chosen through a rigorous review process from a large pool of applicants.

Our President & CEO, Mr.Hideaki Sato, will participate in the final pitch session.
The event will provide an opportunity to introduce our nucleic acid drug discovery platform based on modified nucleic acid technology, as well as our research and development approach and commitment to creating value.

Please click here for more information. (Japanese only)